Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.55 |
| ▸ | AURKA | O14965 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.46 |
| ▸ | TPX2 | Q9ULW0 | 4/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.44 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747385 | 0.92 | KDR (0.57) | KDRAURKAAURKBTPX2MAPK14 | |
| SCHEMBL2747170 | 0.90 | KDR (0.54) | KDRMAPK14BRAFTNNI3KRET | |
| SCHEMBL2749014 | 0.88 | KDR (0.60) | KDRMAPK14BRAFTNNI3KRET | |
| SCHEMBL2747095 | 0.88 | KDR (0.59) | KDRAURKAAURKBTPX2MAPK14 | |
| SCHEMBL4548719 | 0.85 | KDR (0.55) | KDRMAPK14BRAFTNNI3KMAP3K7 | |
| SCHEMBL2747258 | 0.84 | KDR (0.58) | KDRAURKBMAPK14BRAFTNNI3K | |
| SCHEMBL2749094 | 0.83 | KDR (0.78) | KDRRETFLT1 | |
| SCHEMBL2748268 | 0.82 | KDR (0.46) | KDRAURKAAURKBMAPK14BRAF | |
| SCHEMBL2748351 | 0.75 | KDR (0.80) | KDR | |
| SCHEMBL2748912 | 0.75 | KDR (0.80) | KDRRETPDGFRAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885AURKA 4148/4885AURKB 3402/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885AURKA 4148/4885AURKB 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.